Clinical trial · Observational
Molecular Breast Imaging: A Novel Technology for Detection of Malignant Breast Lesions
Molecular Breast Imaging: A Novel Technology for Detection of Malignant Breast Lesions.
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Detection of breast cancer as early as possible is an ongoing imaging challenge.The purpose of the current study is to assess the clinical performance of the new scintigraphic technology, a dedicated breast gamma camera composed by the new generation of CZT detectors,for assessment of breast pathology specifically in women where current imaging techniques, mainly mammography are suboptimal. These cohort are patients with dense breast tissue and patients who are at high risk for breast cancer by a combination of other metrics, including family history and genetic testing. BRCA (breast cancer susceptibility gene), is particularly a relevant health problem among Ashkenazi Jews in Israel.
Conditions
Conditions (4)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Dense Breast Tissue | — | UNRESOLVED | — |
| Discrepancy With Clinical Examination | — | UNRESOLVED | — |
| Equivocal Mammographic, Sonographic or MRI Lesion | — | UNRESOLVED | — |
| Small Breast Lesions | — | UNRESOLVED | — |
Interventions
Interventions (0)
Data not yet available
Design
Arms and outcomes
Arms (4)
- label
- Women with equivocal findings on Mammography, US and/or MRI
- description
- Women with equivocal findings on Mammography, US and/or MRI
- label
- Discrepancy between clinical examination and imaging
- description
- Women with discrepancy between clinical examination and breast imaging
- label
- Women with dense breast
- description
- Women with dense breast
- label
- Women in high risk for Breast Cancer
- description
- Women in high risk for Breast Cancer. Including patients with genetic high risk and/or strong family history.
Primary outcomes (1)
- measure
- Detection of unexpected malignant lesions. Ruling out malignant lesions in case of equivocal lesions identified by clinical examination, mammography, US and/or MRI.
Eligibility
Eligibility (as posted)
- Sex
- Female
- Minimum age
- 25 Years
Show eligibility criteria text
Inclusion Criteria: * Age over 25. * Equivocal breast lesions. * Dense breast tissue. * High-risk for breast cancer Exclusion Criteria: * Age under 25. * Pregnancy. * Patients unable to understand and sign an informed consent
References
Publications (3)
- BACKGROUNDHruska CB, Phillips SW, Whaley DH, Rhodes DJ, O'Connor MK. Molecular breast imaging: use of a dual-head dedicated gamma camera to detect small breast tumors. AJR Am J Roentgenol. 2008 Dec;191(6):1805-15. doi: 10.2214/AJR.07.3693. PMID 19020253
- BACKGROUNDHruska CB, Boughey JC, Phillips SW, Rhodes DJ, Wahner-Roedler DL, Whaley DH, Degnim AC, O'Connor MK. Scientific Impact Recognition Award: Molecular breast imaging: a review of the Mayo Clinic experience. Am J Surg. 2008 Oct;196(4):470-6. doi: 10.1016/j.amjsurg.2008.06.005. Epub 2008 Aug 23. PMID 18723155
- BACKGROUNDHruska CB, O'Connor MK. Quantification of lesion size, depth, and uptake using a dual-head molecular breast imaging system. Med Phys. 2008 Apr;35(4):1365-76. doi: 10.1118/1.2885371. PMID 18491531